Regencell Property Plant Equipment vs Current Deferred Revenue Analysis
| RGC Stock | USD 5.35 0.25 4.90% |
Regencell Bioscience financial indicator trend analysis is much more than just breaking down Regencell Bioscience prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Regencell Bioscience is a good investment. Please check the relationship between Regencell Bioscience Property Plant Equipment and its Current Deferred Revenue accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regencell Bioscience Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.
Property Plant Equipment vs Current Deferred Revenue
Property Plant Equipment vs Current Deferred Revenue Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Regencell Bioscience Property Plant Equipment account and Current Deferred Revenue. At this time, the significance of the direction appears to have weak relationship.
The correlation between Regencell Bioscience's Property Plant Equipment and Current Deferred Revenue is 0.39. Overlapping area represents the amount of variation of Property Plant Equipment that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Regencell Bioscience Holdings, assuming nothing else is changed. The correlation between historical values of Regencell Bioscience's Property Plant Equipment and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Property Plant Equipment of Regencell Bioscience Holdings are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Property Plant Equipment i.e., Regencell Bioscience's Property Plant Equipment and Current Deferred Revenue go up and down completely randomly.
Correlation Coefficient | 0.39 |
| Relationship Direction | Positive |
| Relationship Strength | Very Weak |
Property Plant Equipment
Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.Most indicators from Regencell Bioscience's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Regencell Bioscience current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regencell Bioscience Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. At present, Regencell Bioscience's Enterprise Value Over EBITDA is projected to decrease significantly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 8.47, whereas Selling General Administrative is forecasted to decline to about 3.8 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 7.6M | 6.3M | 5.6M | 5.4M | Cost Of Revenue | 604.4K | 769.7K | 885.1K | 840.9K |
Regencell Bioscience fundamental ratios Correlations
Click cells to compare fundamentals
Regencell Bioscience Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Regencell Bioscience fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 514.0K | 340.1K | 18.0M | 12.6M | 11.4M | 10.8M | |
| Short Long Term Debt Total | 3.1M | 3.7M | 771.3K | 463.7K | 417.3K | 396.4K | |
| Total Current Liabilities | 3.2M | 4.3M | 577.8K | 606.9K | 546.2K | 518.9K | |
| Total Stockholder Equity | (2.7M) | (4.0M) | 17.1M | 12.0M | 10.8M | 11.4M | |
| Net Debt | 2.7M | 3.6M | (5.6M) | (1.1M) | (991.0K) | (941.5K) | |
| Retained Earnings | (2.7M) | (4.0M) | (11.4M) | (17.3M) | (15.6M) | (14.8M) | |
| Cash | 387.0K | 59.4K | 6.4M | 1.6M | 1.4M | 1.3M | |
| Non Current Assets Total | 127.0K | 273.3K | 1.6M | 1.0M | 900.4K | 855.4K | |
| Cash And Short Term Investments | 387.0K | 59.4K | 16.4M | 11.6M | 10.4M | 9.9M | |
| Liabilities And Stockholders Equity | 514.0K | 340.1K | 18.0M | 12.6M | 11.4M | 10.8M | |
| Non Current Liabilities Total | 3.1M | 3.7M | 360.3K | 25.4K | 29.2K | 27.8K | |
| Total Liab | 3.2M | 4.3M | 938.0K | 632.3K | 569.1K | 540.6K | |
| Total Current Assets | 387.0K | 66.8K | 16.4M | 11.6M | 10.5M | 9.9M | |
| Short Term Debt | 3.1M | 3.7M | 411.0K | 438.3K | 394.4K | 374.7K | |
| Net Invested Capital | 419.0K | (315.7K) | 17.1M | 12.0M | 13.8M | 14.5M | |
| Net Working Capital | (2.8M) | (4.3M) | 15.9M | 11.0M | 12.7M | 13.3M |
Currently Active Assets on Macroaxis
When determining whether Regencell Bioscience offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regencell Bioscience's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regencell Bioscience Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regencell Bioscience Holdings Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regencell Bioscience Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Regencell Bioscience information on this page should be used as a complementary analysis to other Regencell Bioscience's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Complementary Tools for Regencell Stock analysis
When running Regencell Bioscience's price analysis, check to measure Regencell Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regencell Bioscience is operating at the current time. Most of Regencell Bioscience's value examination focuses on studying past and present price action to predict the probability of Regencell Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regencell Bioscience's price. Additionally, you may evaluate how the addition of Regencell Bioscience to your portfolios can decrease your overall portfolio volatility.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |
Is Regencell Bioscience's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regencell Bioscience. If investors know Regencell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regencell Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.45) | Return On Assets (0.26) | Return On Equity (0.42) |
The market value of Regencell Bioscience is measured differently than its book value, which is the value of Regencell that is recorded on the company's balance sheet. Investors also form their own opinion of Regencell Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Regencell Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regencell Bioscience's market value can be influenced by many factors that don't directly affect Regencell Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regencell Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Regencell Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regencell Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.